Table 3: Univariate and multivariate analyses of relationship between various clinical factors and recurrence-free survival (RFS).

VariableCategoryObsUnivariate analysis; RFSMultivariate analysis; RFS
HRP95%CIHRP95%CI

GenderM/F48/380.7860.2780.508-1.215
Age<64/≥6440/461.6500.0231.071-2.5421.3360.2150.845-2.113
PLT, 109/L<258.67/≥258.6764/220.6770.1240.413-1.112
PDW, fL<17.99/>=17.9964/220.9960.9860.609-1.627
MPV, fL<12.46/>=12.4664/221.1010.7000.675-1.794
LYM, 109/L<1.5/>=1.564/220.6910.1430.422-1.133
NEU, 109/L<7.12/>=7.1264/221.1470.5820.704-1.868
PLR<240.18/>=240.1866/200.9810.9410.586-1.642
NLR<6.17/>=6.1765/211.5900.0690.965-2.622
APTT, s<30.8/≥30.864/220.9500.8380.578-1.559
PT, s<12.3/≥12.364/221.8270.0191.105-3.0181.8260.0331.049-3.177
INR<1.07/≥1.0764/221.8270.0191.105-3.018
FIB, g/l<4.49/≥4.4964/221.2400.3970.753-2.04
TT, s<18.75/≥18.7565/210.8000.3790.487-1.315
DD, ug/mL<1.11/≥1.1163/211.4100.1620.871-2.285
ALB, g/L<35/≥3538/480.5610.0110.359-0.8770.9390.8200.547-1.612
CRP, mg/L<10/≥1025/611.2840.3010.799-2.064
GPS0/1-219/671.2890.3380.767-2.167
CA199, U/ml<37/>=3728/581.1950.4470.755-1.889
CA125, U/ml<36.49/≥36.4959/270.9320.7650.589-1.476
CEA, ng/ml<5.1/≥5.157/291.1200.6260.711-1.763
DifferentiationMiddle-High/Low57/293.3840.0012.021-5.6673.0900.001 1.748-5.461
Lymph(+)/(-)39/470.6900.0940.447-1.064
Nerve(+)/(-)60/260.6920.1240.433-1.107
StageI-II/III-IVA62/242.1540.0031.295-3.5832.0400.0081.201-3.467

Obs, observation, PLT, platelet count, PDW, platelet distribution width, MPV, mean platelet volume, LYM, lymphocyte count, NEU, neutrophil count, PLR, platelet-lymphocyte ratio, NLR, neutrophil-lymphocyte ratio, ALB, albumin, CRP, C-reactive protein, GPS, Glasgow Prognostic Score, APTT, activated partial thromboplastin time, PT, prothrombin time, INR, international normalized ratio, FIB, fibrinogen, TT, thrombin time, DD: D-dimer, Lymph: lymph node metastasis, and Nerve, nerve invasion. OS, overall survival and RFS, recurrence-free survival.